![](/wp-content/uploads/2024/05/Screenshot-2024-05-02-at-5.47.04%E2%80%AFPM.png)
$599
Amgen, Regeneron, and Alnylam Q1 ’24 Earnings
Three cardiometabolic-related news items have been observed: Amgen (press release; slides), Regeneron (press release; slides), and Alnylam (press release; slides) hosted their respective Q1 ’24 earnings calls. Below, FENIX provides highlights and insights for the respective news items.